CMM and Qiagen Focus on Molecular Diagnostic Markers

Financial terms of the agreement were not disclosed.

CMM has access to clinical samples, molecular analysis capabilities, and XenoBase-- software and a database system developed at the Van Andel Research Institute (Grand Rapids, MI, USA). This bio-informatic system is capable of analyzing a wide range of molecular and conventional clinical data to help scientists identify clinical associations between diseases, biomarkers, and treatments. Following Qiagen's initial results, CMM might also provide laboratory-based genomics and proteomics services to assist Qiagen in the development and validation of new molecular diagnostic tests.

CMM is a Clinical Laboratory Improvement Amendments (CLIA)-certified, College of American Pathologists (CAP)-accredited, clinical diagnostics laboratory. CMM's capabilities, including XenoBase access, on-site microarray-based DNA typing, and gene expression played a role in bringing Qiagen to West Michigan.

Qiagen is a provider of sample and assay technologies and products that are considered standards in areas such pre-analytic sample preparation and assay solutions in molecular diagnostics, life sciences, and applied testing. Qiagen has developed a comprehensive range of more than 500 consumable products and automated systems for sample collection, nucleic acid and protein handling, separation, and purification, and open and target specific assays.


Related Links:
Center for Molecular Medicine
Qiagen
Van Andel Research Institute